Abstract
After years of standard care prescribed to cancer patients without any selection except the primary site and histology of the tumour, the era of precision medicine has revolutionised cancer care. Personalised medicine refers to the selection of patients for specific treatment based on the presence of specific biomarkers which indicate sensitivity to corresponding targeted therapies and/or lower toxicity risk, such that patients will have the greatest chance of deriving benefit from the treatments. Here, we review personalised medicine for nonsmall cell lung cancer.
Abstract
Herein we review personalised medicine for nonsmall cell lung cancer http://ow.ly/LiiI30fXUlJ
Footnotes
Number 3 in the Series “Personalised medicine in respiratory diseases” Edited by Renaud Louis and Nicolas Roche
Previous articles in this series: No. 1: Chung KF. Personalised medicine in asthma: time for action. Eur Respir Rev 2017; 26: 170064. No. 2: Bonsignore MR, Suarez Giron MC, Marrone O, et al. Personalised medicine in sleep respiratory disorders: focus on obstructive sleep apnoea diagnosis and treatment. Eur Respir Rev 2017; 26: 170069.
Conflict of interest: Disclosures can be found alongside this article at err.ersjournals.com
Provenance: Commissioned article, peer reviewed.
- Received June 1, 2017.
- Accepted September 1, 2017.
- Copyright ©ERS 2017.
ERR articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.